Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients with advanced cancers. (Abstract 1519O)
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses study findings on chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Abstract LBA37)
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
Mansoor Raza Mirza, MD, of Rigshospitalet, Copenhagen University Hospital, discusses phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer. (Abstract LBA3)
Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)
Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario 12 De Octubre, discusses in Spanish overall survival data on afatinib vs gefitinib in patients with EGFR mutation–positive non–small cell lung cancer. (Abstract LBA43)
